{"id":17157,"date":"2021-03-29T10:25:41","date_gmt":"2021-03-29T08:25:41","guid":{"rendered":"http:\/\/mabdesign.fr\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/"},"modified":"2021-03-29T10:25:41","modified_gmt":"2021-03-29T08:25:41","slug":"angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/","title":{"rendered":"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization"},"content":{"rendered":"<p class=\"p1\"><i>QUEBEC CITY, QC CANADA, Val-de-Reuil, Normandy, FRANCE and AUSTIN, TX, March 24<\/i><span class=\"s1\"><i><sup>th<\/sup><\/i><\/span><i>, 2021.<\/i> Dr Louis-Philippe V\u00e9zina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.<\/p>\n<p class=\"p1\">Angany recently announced the successful production of NAbs derived from the plasma of COVID 19 patients using Angany\u2019s plant-based production platform.<span class=\"Apple-converted-space\">\u00a0 <\/span>This work, in collaboration with Pr. Rogier W. Sanders and Dr Marit van Gils of University Medical Centers in Amsterdam (Amsterdam UMC), demonstrated the efficacy of therapeutic NAbs rapidly developed for COVID-19 and its variants.<span class=\"Apple-converted-space\">\u00a0 <\/span>This approach represents an anti-viral treatment that adds another pharmaceutical weapon against viral disease, one that can adapt quickly to the ongoing problem of viral mutation. <a href=\"https:\/\/angany.com\/angany-canada-france-and-phylloceuticals-usa-two-biotechnology-innovators-team-up-to-accelerate-covid-nabs-commercialization\/\" target=\"_blank\" rel=\"noopener noreferrer\">To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr Louis-Philippe V\u00e9zina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32],"tags":[],"class_list":["post-17157","post","type-post","status-publish","format-standard","hentry","category-news","category-our-members"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization - MabDesign<\/title>\n<meta name=\"description\" content=\"Dr Louis-Philippe V\u00e9zina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Dr Louis-Philippe V\u00e9zina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-29T08:25:41+00:00\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization\",\"datePublished\":\"2021-03-29T08:25:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/\"},\"wordCount\":152,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/\",\"name\":\"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"datePublished\":\"2021-03-29T08:25:41+00:00\",\"description\":\"Dr Louis-Philippe V\u00e9zina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization - MabDesign","description":"Dr Louis-Philippe V\u00e9zina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/","og_locale":"en_US","og_type":"article","og_title":"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization - MabDesign","og_description":"Dr Louis-Philippe V\u00e9zina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.","og_url":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/","og_site_name":"MabDesign","article_published_time":"2021-03-29T08:25:41+00:00","author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization","datePublished":"2021-03-29T08:25:41+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/"},"wordCount":152,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/","url":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/","name":"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"datePublished":"2021-03-29T08:25:41+00:00","description":"Dr Louis-Philippe V\u00e9zina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the two companies will team up to accelerate the development of a preventive and curative product based on neutralizing monoclonal antibodies (NAbs) against SARS CoV-02 and its variants.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/angany-and-phylloceuticals-team-up-to-accelerate-covid-nabs-commercialization\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Angany and Phylloceuticals team up to accelerate Covid NAbs commercialization"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=17157"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17157\/revisions"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=17157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=17157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=17157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}